Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL.
Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24(39):6058-68.
2. Matsuoka M, Jeang KT. Human T-cell leukemia virus type I at age 25: a progress report. Cancer Res 2005; 65(11):4467-70.
3. Verdonck K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7(4):266-81.
4. Vrielink H, Reesink HW. HTLV-I/II prevalence in different geographic locations. Transfus Med Rev 2004; 18(1):46-57.
5. Meytes D, Schochat B, Lee H, Nadel G, Sidi Y, Cerney M,
et al
. Serological and molecular survey for HTLV-I infection in a high-risk Middle Eastern group. Lancet 1990; 336(8730):1533-5.
6. Farid R, Shirdel A, Tabei SZ .Clinical manifestation of adult T cell lymphoma/ leukemia associated with HTLV-I in north-eastern Iran. Iranian J Med Sci 1992; 17:105-108.
7. Safai B, Huang JL, Boeri E, Farid R, Raffat J, Schutzer P,
et al
. Prevalence of HTLV type I infection in iran: a serological and genetic study. AIDS Res Hum Retroviruses 1996; 12(12):1185-90.
8. Rezvan H, Ahmadi J, Farhadi M. A cluster of HTLV-I infection in northeastern of Iran. Transfusion Today 1996; 7:8-9.
9. Abbaszadegan MR, Gholamin M, Tabatabaee A, Farid R, Houshmand M, Abbaszadegan M. Prevalence of human T-lymphotropic virus type 1 among blood donors from Mashhad, Iran. J Clin Microbiol 2003; 41(6):2593-5.
10. Tarhini M, Kchour G, Sayadpour Zanjani D, Rafatpanah H, Otrock ZK, Bazarbachi A, Farid R. Declining tendency of human T-cell leukaemia virus type I carrier rates among blood donors in Mashhad, Iran. Pathology 2009; 41:5,498-9.
11. Farid R, Etemadi M, Baradaran H, Nikbin B. Seroepidemiology and virology of HTLV-I in the city of Mashhad, northeastern Iran. Serodiagnosis and immunotherapy in infectious disease 1993; 5(4): 251-2.
12. Farid Hosseini R, Etemadi MM, Baradaran H, Malek Nejad A, Amina H, Shahriari Z. Seroepidemiology of HTLV-I in the city of Mashhad. J Med Counc Islam Repub Iran 1996; 4(13): 318-21 (Persian).
13. Ajami A, Hosseini RF, Tabarestani N. Seroepidemiological survey of HTLV-I/II in blood donors of Mazandaran in 1999. J Mazandaran Univ Med Sci 2000; 10:45-48 (Persian).
14. Tavanai Sani A. Serologic Prevalence of HTLV among Blood Donors in Mashhad (Northeastern Iran). Arch Iranian Med 2001; 4(1):25-6.
15. Arjmandi F. HTLV-I prevalence in patients with leukemia/lymphoma and normal population. J Res Med Sci (JRMS) 2001; 6:147-8 8 (Persian).
16. Arjmandi F, Shahriari M, Sadeghi Hasanabadi A. A Comparative study of the prevalence of HTLV – I infection in Leukemia / non- Hodgkins lymphoma patients, thalassemic patients and blood donors. J Sahid Sadoughi Univ Med Sci 2003; 10(4):25-8 (Persian).
17. PourKarim MR, Khamisi Pour Gh.R, Zandi K, Roustaei MH. Prevalence of anti-HTLV-I & anti- HTLV-II antibodies in blood donors in Bushehr province. Iranian South Med J 2004; 6(2):161-4 (Persian).
18. Karimi A, Nafici MR, Imani R. Comparison of Human T- cell Leukemia Virus Type-1 (HTLV-I) Seroprevalence in High Risk Patients (Thalassemia and Hemodialysis) and Healthy Individuals from Charmahal-Bakhtiari Province. Kuwait Med J 2007; 39(3): 259-61.
19. Rostamzadeh Khameneh Z, Baradaran M, Sepehrvand N. Survey of the seroprovalence of HTLV I/II in hemodialysis patients and blood donors in Urmia. Saudi J Kidney Dis Transpl 2008; 19(5):838-41.
20. Falahi S, Sabahi F, Zeynali M, Kiani J, Ranjbari J. Incidince of human T-lymphotropic virus type 1 (HTLV-I) among blood donors from Ilam, Iran. Ir J Virol 2008;1(3):11-4.
21. Abedi F, yavaian M, Shakibzadeh A, Khalvati B, Asadi AH. A pilot Seroepidemiologic study of HTLV in thalassemia, hemophilia, and hemodialysed patients in Hormozgan. Med J Hormozgan Univ 2009; 13(2):75-80 (Persian).
22. Sayadpour Zanjani D, Shahabi M, Talaei N, Afzalaghaee M, Tehranian F, Bazargani R. Molecular analysis of human T cell lymphotropic virus type 1 and 2 (HTLV-I/2) seroindeterminate blood donors from Northeast Iran: evidence of proviral tax, env, and gag sequences. AIDS Res Hum Retroviruses 2010; 26(12):1-5.
23. Ghafouri M, Ameli MR. Transfusion transmitted viral infections in blood donors of South Khorasan. Blood Quart (Sci J Iranian Blood Transfus Org) 2011;7(4):242-8 (Persian).
24. Kazemi Arababadi M, Mohammadzadeh A, Pourfathollah AA, Kennedy D. Polymorphisms within Fas gene are not associated with occult hepatitis B virus infection. Hepat Mon 2011;11:23-6.
25. Haghighi S, Jalalian M, Bazargani R, Motamedi R. Co-infection between HTLV-I,2 and other transfusion transmissible viral infections in Mashhadi blood donors. Proceedings of the 1st international congress on HTLV-I and associated diseases in Iran. Mashhad, Iran, 2010 Feb 18-20. P-12.
26. Shahabi M, Sayadpour Zanjani D, Tehranian F. Seroindeterminate HTLV-I/II prevalence and characteristics in blood donors of Northeast of Iran. Proceedings of the 1st international congress on HTLV-I and associated diseases in Iran. Mashhad, Iran, 2010 Feb 18-20. O-26.
27. Rakhshan Masoudi Z, Yazdanparast E, Omidkhoda A, Zarei N, Firoozbakhat S, Zarei M. Frequency of human T-lymphotropic virus type 1,2 among Blood Donors from Karaj transfusion centre. Proceedings of the 1st international congress on HTLV-I and associated diseases in Iran. Mashhad, Iran, 2010 Feb 18-20. P-30.
28. Mortezaee Z. Serologic frequency of HTLV-I and HTLV-II among blood donors and its relation with blood cells changes. Student Thesis, University of Esfahan, Faculty of Sciences, 2007 (Persian).
29. Talebian A, Amini kafiabad S. Prevalence of Anti-HTLV-I/II among blood donors in blood transfusion centres of 27 provinces of Iran. Research project, Iranian Blood Transfusion Organization, 2006 (Persian).
30. Morshedi B. Investigation of HTLV-I among blood donors in Isfahan Blood Transfusion Organization. Research project, Isfahan University of Medical Sciences, 1996-1997 (Persian).
31. Prevalence of HTLV-I/2 infections among blood donors in Ahvaz Blood Transfusion Organization. Research project, Ahvaz University of Medical Sciences, 1998 (Persian).
32. Rezvan H, Farhadi M, Ahmadi J, Tarvian S. Preliminary survey of frequency of HTLV-I/II among blood donors in Iran. Blood J (Sci J Iranian Blood Transfus Org) 1995;2(1):23-8 (Persian).
33. Rafatpanah R, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SKh, Ahmadi S,
et al
. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: A population-based seroepidemiology survey. J Clin Virol 2011; 52(3):172-6.
34. Hedayati-Moghaddam MR, Fathimoghadam F, Eftekharzadeh Mashhadi I, Soghandi L, Bidkhori HR. Epidemiology of HTLV-I in Neyshabour, Northeast of Iran. Iran Red Cresc Med J 2011;13(6): 424-7.
35. Azarpazhooh MR, Hasanpour K, Ghanbari M, Rezaee SAR, Mash
201
kani B, Hedayati-Moghaddam MR,
et al
. Human t-lymphotropic virus type 1 prevalence in northeastern iran, sabzevar: An epidemiologic-based study and phylogenetic analysis. AIDS Res Hum Retroviruses 2012;28(9):895-901.
36. Rezvan H, Abolghassemi H, Kafiabad SA. Transfusion-transmitted infections among multitransfused patients in Iran: a review. Transfus Med 2007;17(6):425-33.
37. Oguma S, Imamura Y, Kusumoto Y, Nishimura Y, Yamaguchi K, Takatsuki K,
et al
. Accelerated declining tendency of human T-cell leukemia virus type I carrier rates among younger blood donors in Kumamoto, Japan. Cancer Res 1992; 52:2620–3.
38. Abolghasemi H, Maghsudlu M, Amini Kafi-Abad S, Cheraghali A. Introduction to Iranian Blood Transfusion Organization and Blood Safety in Iran. Iranian J Publ Health 2009;38(Suppl 1):82-7.
39. Senyuta N, Syrtsev A, Yamashita M, Stepina V, Susova O, Scherbak L,
et al
. Sero-epidemiologic and phylogenetic studies of HTLV-I infection in 2 countries of the Caspian Sea region. Int J Cancer 1998;77:488-93.
40. Al-Mufti S, Voevodin A, Ahmed S, Al Hamdan S, Al-Basheer AA. Seroprevalence of Human T-Cell Leukemia/Lymphoma Virus Type I and Type II (HTLV-I/HTLV-II) Infection among Volunteer Blood Donors in Kuwait. Med Principles Pract 1999;8:45-50.
41. Fawaz NA, Tamim H, Almawi WY. Low prevalence of antibodies to human T-lymphotropic virus-I/II among blood donors in eastern Saudi Arabia. Am J Infect Control 2005;33(3):189-91.
)